Compare iShares Core High Dividend ETF (HDV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Core High Dividend ETF trades at $28.14, while Regeneron Pharmaceuticals Inc trades at $674.82 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| HDV | REGN | |
|---|---|---|
52-Week High | $28.36 | $812.27 |
52-Week Low | $23.64 | $545.46 |
Market Cap | — | $70.47B |
Sector | — | Health |
Enterprise Value | — | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a 3.0% dividend yield, with recent payouts of $0.19 and $0.09 per share. News coverage highlights HDV's defensive sector focus and competitive expense ratio compared to peers like SCHD and VYM, though some analysts note concentration risk in energy holdings.
Outlook remains cautiously positive given HDV's low volatility and income appeal, but investors face risks from oil price sensitivity and modest dividend growth. The ETF's quality screen provides stability, yet sector concentration may limit upside if energy underperforms.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
